HomePipelinePNB-001COVID-19 Lung Inflammation

PNB-001

COVID-19 Lung Inflammation

PNB-001 for the Treatment of Lung Infection/Inflammation

Molecule
PNB-001
Development status
Phase 3 approved · currently stopped because of the Omicron variant
Therapeutic area
Immune & inflammation
Biological action
CCK ligand, lymphokine
Therapeutic target
T cells, lymphokine
Therapeutic indication
Lung Inflammation (pneumonia), COVID-19

Stage of development

  • PNB-001

    COVID-19 Lung InflammationCCK ligand, lymphokine

Graph of the stage of development of PNB-001 in COVID-19 Lung Inflammation. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Background about target

The peptide cholecystokinin (CCK) was originally discovered in the gastrointestinal tract and has been shown to mediate pancreatic secretion and contraction of gallbladder. CCK was then described in the mammalian central nervous system (CNS) as a gastrin-like immunoreactive material. Two types of CCK receptors (type A, “alimentary”, and type B, “brain”) have been distinguished. CCK-A and CCK-B receptor types have been shown to differ by their relative affinity for the natural ligands, their differential distribution, and their molecular structure. In Dengue fever death rate in man and in mice correlated with the degree of inflammation. Inflammation and death rate were reduced by PO administration of PNB-001 by 80%. Current corona SARS2 pandemic is terminal as inflammatory disease and key to treatment is the reduction of the cytokine storm, monitored by biomarker IL-6.

Preclinical studies:

PNB-001 is a CCK A receptor agonist and CCK receptor antagonist.

PNB-001 was tested in a rat model of indomethacin-induced IBD and was compared to positive control, prednisolone. PNB-001, at 5 mg/kg and 20 mg/kg p.o., was extremely effective in reducing the inflammation- and IBD-dependent damage to various gastrointestinal tissues and organs. Gross pathological changes and histopathological observations demonstrating IBD and Crohn’s Disease in this animal model were completely reversed by PNB-001. The anti-inflammtory effect is general and in the rat paw edema PNB-001 is highly efficient at 10 mg/kg and showed in the Baker’s yeast model in mice a potent antipyretic effect.

The formalin test and the carrageenan induced are classical inflammatory assays and carrageenan induced smelling is mediated by cytokines. In a Dengue fever viremia model PNB-001 was tested for efficacy in Dengue fever using NMRI mice. At a dose of 10 mg /kg death rate is reduced by 70-80% and inflammation marker IL-6 is reduced accordingly. Mice were injected with unadapted Dengue virus, resulting in a dose-dependent transient viremia lasting several days. Increased levels of pro-inflammatory cytokine IL-6 was measured to provide experimental evidence of the key involvement of inflammation.

Oral administration of the gastrin antagonist PNB001, led to a reduction of splenomegaly and proinflammatory cytokine levels and most importantly death. The results validate the experimental agent to be studied clinically in viral diseases, in which death is triggered by inflammation, such as COVID-19.

Preclinical development studies:

PNB-001 has a short half-life of 1.20 min in rat liver microsome and approximately 12 min in dogs and human liver microsome. PNB-001 was evaluated in various ADME studies, including cytochrome P450 enzyme inhibition, plasma protein binding, and CaCo2 permeability. With 97% of PNB-001 bound to rat and human plasma, the amount of free unbound PNB-001 is comparable to some of the marketed drugs. CaCo2 permeability studies indicated that PNB-001 has high permeability and is not effluxed in the B>A direction.

Regulatory toxicology and safety pharmacology studies demonstrate extremely high levels of safety and tolerability. Doses selected were 50 to 100 fold above the efficacy dose.

Synthetic chemistry:

PNB-001 synthetic schema has been established both in non-GMP and in GMP conditions. Moreover, synthetic chemistry efforts are optimized to synthesize PNB-001 one a multi kg scale.

Formulation studies:

Formulation development provided 100mg hard gelatin capsule with excipients, fully optimized for product launch.

Phase I clinical trials:

Phase I SAD clinical trial protocols have been completed and PNB-001 was found extremely safe over the dose range from 25-1500 mg. PNB-001, Baladol®, was tested now in 74 healthy subjects in clinical phase 1. Following a SAD study with 42 subjects Baladol® was tested in MAD, (multiple ascending doses) at low, medium and high doses over a period of 14 days in 32 healthy subjects. Overall, Baladol® was tested safe and with an efficient therapeutic window. From 32 subjects 30 completed the MAD trial and only 2 adverse reactions were observed.

Phase 2 clinical trials

PNB-001 was tested safe and efficient. In summary hospitalisation rate and oxygen supplementation was reduced and in terms of biomarkers at cellular level NLR was restored into the healthy range. Inflammation markers, as ESR and CRP as well as IL6, were reduced at 2 weeks and the clinical markers correlated well with clinical outcome for the phase 2 clinical trial.

Phase 3 clinical trials

After completing of phase 2 results were presented to the DGCI and phase 3 was approved, however patients were not enrolled due to lack of patients.

Intellectual property

Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. Examination by the PTO office in Washington DC did not find any infringement issues with this series of molecules. USPTO has issued the patent on December 28, 2014. An Indian patent was filed in May 2020 and a full examination was requested.

A user patent, to include the immune modulation properties from phase 2, was filed in 2022 and with provide patent protection until 2042.

About PNB-001

Clinical · Phase 1 and Phase 2 completed

The front runner of the portfolio.
Developed from immune-mediated
Inflammatory research, PNB-001 is in Phase 3 for Covid-19 and has completed Phase 2 in Ulcerative Colitis & Crohn's Disease

PNB-001 full profile

Other indications of PNB-001

CNS & addiction

All molecules

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.